AI news impact · China A-shares
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A (002603) news impact
On 2026-10-30 Wave Radar's AI rated the news on Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A as neutral (impact score +35%).
Yiling Pharma posted 9M revenue of 5.968 billion yuan and net profit of 1.096 billion yuan (+9.55% YoY), with operating cash flow up 25.86%.
- Direction
- Neutral
- Impact score
- +35%
- Confidence
- 85%
- Headlines read
- 4
- Date
- 2026-10-30
AI assessment
Steady 9.55% earnings growth paired with a 25.86% surge in operating cash flow underscores healthy financial operations.
Sector impact
Steady performance offers positive support for traditional Chinese medicine peers with moderate spillover.
Headlines the AI read
- 以岭药业前三季度营收59.68亿元 经营性净现金流同比增长25.86% AkShare/经济参考报 · 2026-10-30
- 微型神经芯片实时监测药物对大脑影响;脑虎科技完成B轮融资 AkShare/21世纪经济报道 · 2026-10-29
- 以岭药业:2026年前三季度净利润10.96亿元 同比增长9.55% AkShare/中国证券报·中证网 · 2026-10-28
- 以岭药业前三季度净利润10.96亿元,经营现金流同比增25.86% AkShare/财联社 · 2026-10-28
Rating history
One rating per trading day the stock was covered.
More on Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.